HC Wainwright & Co. Maintains Buy on Alumis, Lowers Price Target to $25
3/30/2026
Impact: -50
Healthcare
HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on Alumis (NASDAQ: ALMS) but has lowered the price target from $40 to $25.
AI summary, not financial advice
Share: